Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.3)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 1, January-February, p. 57–61

doi: 10.17219/acem/42197

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Induction and maintenance infliximab therapy in children with moderate to severe ulcerative colitis: Retrospective, multicenter study

Barbara M. Iwańczak1,A,B,C,D,E,F, Jarosław Kierkuś2,B,C,F, Józef Ryżko2,B,C,E,F, Mariusz Szczepanik3,B,C,F, Sabina Więcek4,B,C,F, Grażyna Czaja-Bulsa5,B,C,F, Magdalena Kacperska5,B,C,F, Bartosz Korczowski6,B,C,F, Jolanta Maślana7,B,C,F, Franciszek Iwańczak1,B,C,E,F

1 2nd Department of Paediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, Poland

2 Children’s Memorial Health Institute, Warsaw, Poland

3 Department of Pediatric Gastroenterology and Metabolic Disorders, Poznan University of Medical Science, Poland

4 Department of Pediatrics, Medical University of Silesia, Gastroenterology Unit, Upper Silesian Child Health Care Center, Katowice, Poland

5 Pediatric Nursery Unit of Pomeranian Medical University, Division of Pediatrics, Gastroenterology and Reumatology of Zdroje Hospital, Szczecin, Poland

6 Department of Pediatrics, State Hospital no. 2, Rzeszów, Poland

7 Province Children’s Hospital, Kielce, Poland

Abstract

Background. Pediatric ulcerative colitis (UC) is a severe disease characterised by the presence of extensive inflammatory lesions in the colon. The administration of intravenous corticosteroids is recommended in patients with acute relapse of the disease, whereas early treatment with cyclosporine, tacrolimus or infliximab is recommended if there is no improvement.
Objectives. The aim of this study was to retrospectively evaluate the efficacy and safety of infliximab therapy in the treatment of moderate-to-severe and severe relapse of pediatric UC.
Material and Methods. The analysis included 42 children aged 4–18 years (23 girls, 19 boys) treated in 7 pediatric gastroenterology departments in Poland during the past 4 years. The disease duration ranged from 2 to 100 months. The clinical activity of UC ranged from 35 to 85 points according to the PUCAI scale. Twenty-one children were diagnosed with pancolitis, 10 children with extensive UC, and the remaining with the left-sided UC. In the induction therapy infliximab was administered at doses of 5 mg/kg in the 0.2 and 6 weeks, and after the clinical response every 8 weeks to 12 months. Treatment results were assessed in 10 and 54 weeks.
Results. After the induction therapy the clinical response was achieved in 14 children (33.33%) and clinical remission in 11 children (26.19%). Two children required surgical treatment, and the remaining 2 suffered from anaphylactic shock. After the maintenance therapy clinical remission was maintained in 12 children (57.14%), whereas 3 children required surgery (colectomy).
Conclusion. Infliximab therapy in children with moderate-to-severe UC induces remission and, in some children, proves to be effective in preventing early colectomy.

Key words

children, infliximab, ulcerative colitis

References (22)

  1. Griffiths AM. Specificites of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol. 2004;18:509–523.
  2. Ryżko J, Bartnik W, Socha P, Czubkowski P. Odrębności kliniczne nieswoistych zapaleń jelit u dzieci. Pediatr Pol. 2003;78:355–361.
  3. Turner D, Griffiths AM. Acute severe ulcerative colitis in children: A systematic review. Inflamm Bowel Dis. 2011;17:440–449.
  4. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114–1122.
  5. Dotson JL, Hyams JS, Markowitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr. 2010;51:140–145.
  6. Benchimol EI, Turner D, Mann EH, et al. Toxic megacolon in children with inflamatory bowel disease: Clinical and radiographic characteris-tics. Am J Gastroenterol. 2008;103:1524–1531.
  7. Turner D, Simon PL, Travis SP, et al. Consensus for managing acute severe ulcerative colitis in children: A systematic review and joint state-ment from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol. 2011;106:574–588.
  8. Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: A prospective multicenter study of outcomes and predictors of re-sponse. Gastroenterology. 2010;138:2282–2291.
  9. Iwańczak B, Iwańczak F. Leczenie ciężkiego ostrego rzutu wrzodziejącego zapalenia jelita grubego u dzieci. Pediatr Współcz Gastroenterol Hepatol Żywienie Dziecka. 2011;13:175–179.
  10. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: A prospective mul-ticenter study. Gastroenterol. 2007;133:423–432.
  11. Ford AC, Khan KJ, Sandborn WJ, Hanauer SB, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: Systemic review and meta-analysis. Am J Gastroenterol. 2011;106:644–659.
  12. Turner D, Walsh CM, Benchimol EI, et al. Severe paediatric ulcerative colitis: Incidence, outcomes and optimal timing for second-line thera-py. Gut 2008;57:331–338.
  13. IBD Working Group of the European Society for Paediatric Gastroenterology Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: Recommendations for diagnosis – the Porto criteria. J Pediatr Gastroenterol Nutr. 2005;41:1–7.
  14. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification on the Montreal classification of inflammatory bowel disease: The Paris classi-fication. Inflamm Bowel Dis. 2011;17:1314–1321.
  15. Hyams JS, Davis P, Grancher K, Lerer T, Justinich CJ, Markowitz J. Clinical outcome of ulcerative colitis in children. J Pediatr. 1996;129:81–88.
  16. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: A systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–110.
  17. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
  18. Sylvester FA, Turner D, Draghi A 2nd, et al. Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. Inflamm Bowel Dis. 2011;17:1726–1730.
  19. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, pla-cebo-controlled study. Gastroenterol. 2005;128:1805–1811.
  20. Cucchiara S, Romeo E, Viola F, et al. Infliximab for pediatric ulcerative colitis: A retrospective Italian multicenter study. Dig Liver Dis. 2008;40:260–264.
  21. Hyams J, Damaraju L, Blank M, et al. T72 Study Group. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10:391–399.
  22. Szychta M, Kierkuś J, Dądalski M, Wegner A, Kmiotek J, Ryżko J. Leczenie biologiczne infliksymabem ciężkiej postaci wrzodziejącego zapale-nia jelita grubego u dzieci. Pediatr Współcz Gastroenterol Hepatol Zywienie Dziecka. 2012;14:83–87.
© Wroclaw Medical University